# US 2023/0144625 A1 · Polypeptide for the therapy of glomerular kidney disease and analysis of the course and prognosis of dependent syn-dromes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144625 A1
- Document ID: US20230144625A1
- Status: Published application
- Kind: A1
- Application number: 17/912,181
- Filed: 2021-03-16
- Published: 2023-05-11
- Earliest claimed: 2020-03-18
- Assignees: Friedrich-Alexander-Universitat Erlange-Nurnberg
- Applicants: PHARIS BIOTEC GmbH; Friedrich-Alexander-UniversitäT
- Inventors: Wolf-Georg FORSSMANN; Mario SCHIFFER
- Web page: https://patentgrep.com/patent/US20230144625A1

## CPC

- A61P 13/12: of the kidneys
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C12Y 301/27005: Pancreatic ribonuclease (3.1.27.5)
- G01N 33/5044: {involving specific cell types}
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/922: Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A pharmaceutical composition containing human ribonuclease 1 is disclosed. The molecule according to the invention (or the analogous variants) is suitable for use as a medicament for therapy of renal diseases of various aetiologies. The drug according to the invention causes regeneration of glomerular podocytes. The molecule according to the invention can be further used by analytical determination of blood concentration as a marker of disease progression of renal syndromes and for prognosis and prevention of renal insufficiency as a valuable factor of laboratory medicine.

## Claims

### Claim 1

Pancreatic ribonuclease, in particular human, porcine or bovine pancreatic ribonuclease for use in the treatment of regeneration of functionally impaired glomerular podocytes.

### Claim 2 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1 wherein the treatment of regeneration of functionally impaired glomerular podocytes is a renal disease selected from the group consisting of diabetic nephropathy, nephrotic syndrome, nephritic syndrome, glomerular diseases such as membranous glomerulonephritis, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, IgM nephropathy, membranoproliferative glomerulonephritis, minimal change disease, hypertensive nephrosclerosis and interstitial nephritis, Fabry disease, infections, aminoaciduria, Fanconi syndrome, heavy metal poisoning, sickle cell disease, haemoglobinuria, myoglobinuria, organ rejection, pre-eclampsia, acute renal failure and genetic podocytopathies.

### Claim 3 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1, wherein the ribonuclease has a sequence identity with SEQ ID No. 1 of at least 70%, in particular at least 80%, in particular at least 90%, in particular at least 95%.

### Claim 4 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1 with SEQ ID No 1.

### Claim 5 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1, wherein the treatment of the renal disease is by regeneration of glomerular podocytes.

### Claim 6 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1 in substantially aqueous solution, in particular in aqueous solution with pharmaceutical excipients.

### Claim 7 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1, wherein the ribonuclease is formulated for parenteral administration.

### Claim 8 (depends on 1)

Pancreatic ribonuclease for the use according to claim 1, wherein the ribonuclease is present in an amount of at least one functional molecular unit.

### Claim 9

Use of pancreatic ribonuclease, in particular human pancreatic ribonuclease or hRNase 1 for identifying ribonuclease receptors of renal cells in an assay.

### Claim 10 (depends on 9)

Use according to claim 9 wherein labelled pancreatic ribonuclease is used.

### Claim 11

Use of pancreatic ribonuclease, in particular human pancreatic ribonuclease or hRNase 1 for identifying substrates of pancreatic ribonuclease that are causally related to podocyte degeneration.

### Claim 12

An ex-vivo method for removing substrates of pancreatic ribonuclease which are causally related to podocyte degeneration, in particular extracorporeal methods such as haemodialysis, haemofiltration, haemodiafiltration, peritoneal dialysis, non-specific filters and specific ribonuclease-containing units which cleave target molecules extracorporeally.

### Claim 13

A method for treatment of a disease caused by functionally impaired glomerular podocytes by administering pancreatic ribonuclease to a patient in need thereof.

### Claim 14 (depends on 13)

The method of claim 13 wherein the disease is a renal disease selected from the group consisting of diabetic nephropathy, nephrotic syndrome, nephritic syndrome, glomerular diseases such as membranous glomerulonephritis, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, IgM nephropathy, membranoproliferative glomerulonephritis, minimal change disease, hypertensive nephrosclerosis and interstitial nephritis, Fabry disease, infections, amino-aciduria, Fanconi syndrome, heavy metal poisoning, sickle cell disease, hae-moglobinuria, myoglobinuria, organ rejection, pre-eclampsia, acute renal failure and genetic podocytopathies.

### Claim 15 (depends on 13)

The method according to claim 13 wherein the pancreatic ribonuclease has a sequence identity with SEQ ID No. 1 of at least 70%, in particular at least 80%, in particular at least 90%, in particular at least 95%.

### Claim 16 (depends on 14)

The method according to claim 14 wherein the renal disease is treated by regeneration of glomerular podocytes through administration of the pancreatic ribonuclease.

### Claim 17

Use of pancreatic ribonuclease for manufacturing a medicament for the treatment of functionally impaired glomerular podocytes.

### Claim 18 (depends on 17)

Use of claim 17 wherein the functionally impaired glomerular podocytes are causative for a renal disease selected from the group consisting of diabetic nephropathy, nephrotic syndrome, nephritic syndrome, glomerular diseases such as membranous glo-merulonephritis, focal segmental glomerulosclerosis (FSGS), IgA nephropa-thy, IgM nephropathy, membranoproliferative glomerulonephritis, minimal change disease, hypertensive nephrosclerosis and interstitial nephritis, Fabry disease, infections, amino-aciduria, Fanconi syndrome, heavy metal poison-ing, sickle cell disease, hae-moglobinuria, myoglobinuria, organ rejection, preeclampsia, acute renal failure and genetic podocytopathies.

### Claim 19 (depends on 17)

Use of claim 17 wherein the pancreatic ribonuclease has a sequence identity with SEQ ID No. 1 of at least 70%, in particular at least 80%, in particular at least 90%, in particular at least 95%.

### Claim 20

Use of pancreatic ribonuclease for regenerating ex-vivo functionally impaired glomerular podocytes.
